Journal article

Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin A Randomized Controlled Trial

Michiel L Bots, Ian Ford, Suzanne M Lloyd, Stephane Laurent, Pierre J Touboul, Michael G Hennerici

Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014

Abstract

BACKGROUND AND PURPOSE: Thromboxane prostaglandin receptors have been implicated to be involved in the atherosclerotic process. We assessed whether Terutroban, a thromboxane prostaglandin receptor antagonist, affects the progression of atherosclerosis, as measured by common carotid intima-media thickness and carotid plaques. METHODS: A substudy was performed among 1141 participants of the aspirin-controlled Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) trial. Common carotid intima-media thickness and carotid plaque occurrence was measured during a 3-year period. R..

View full abstract

Grants

Funding Acknowledgements

The work is supported by Servier. The sponsor participated in discussions regarding the design and conduct of the study and provided logistical support during the trial. Monitoring of the study and maintenance of the trial was performed by a contract research organization under contract with the sponsor. Collection, management, and analysis of the data were performed by the sponsor and the contract research organization under contract with the sponsor. The article was prepared by the author group. The sponsor was permitted to review the article and suggest changes, but the final approval of content was exclusively retained by the authors.